Alder BioPharmaceuticals, Transforming the Migraine Treatment Paradigm

Migraine affects 36 million Americans3 and is considered the sixth most disabling disease in the world.4 It is a debilitating neurological disease characterized by recurrent episodes of moderate to severe headache accompanied by nausea, vomiting, and sensitivities to light and sound.4 The occurrence of migraine can be unpredictable with a profound impact on activities of daily living.5 Migraine can last for decades, often during what should be the most productive years of an individual’s life.3

Migraine can remit or progress to chronic migraine over time and persist as chronic migraine for years or decades, but it commonly oscillates between periods of episodic and chronic migraine.3 Historically, preventive treatments for migraine have failed to meet the needs of most patients and many have discontinued use within six months to one year due to lack of efficacy and/or side effects.6,7 Treatment, if effective, may take weeks to months to achieve meaningful clinical benefit.7 Therefore, there is a significant need for rapid, effective, and well-tolerated treatment options for the prevention of migraine.3

Robust Development Pipeline

Alder strives to design best-in-class therapies that address unmet medical needs and have the potential to transform the lives of millions of patients.

3Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015; 55(S2):103-122.

4Migraine Research Foundation. Migraine Facts. Available at: Accessed May 10, 2018.

5Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.

6Bigal ME, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49(7):1028-1041.

7Hepp, Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):477-88.